References
- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
- Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38(4 Suppl):S512–S521.
- McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50.
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031.
- Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530–535.
- National Institute of Health – National Heart Lung and Blood Institute. Evidence-based management of sickle cell disease 2014; [cited 2019 November 4]. Available from: https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease.
- Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644.
- Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11–16.
- Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17–25.
- Cronin RM, Hankins JS, Byrd J, et al. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology. 2019;24(1):189–198.
- Houston-Yu P, Rana SR, Beyer B, et al. Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients. Am J Hematol. 2003;72(3):201–203.
- Ballas SK, Kanter J, Agodoa I, et al. Opioid utilization patterns in United States individuals with sickle cell disease. Am J Hematol. 2018;93(10):E345–E347.
- Ruta NS, Ballas SK. The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med. 2016;17(10):1793–1798.
- Su ZT, Segal JB, Lanzkron S, et al. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997–2017. Pharmacoepidemiol Drug Saf. 2019;28(9):1246–1250.
- Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
- McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758.
- Stettler N, McKiernan CM, Melin CQ, et al. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA. 2015;313(16):1671–1672.
- Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235.
- US Food and Drug Administration. Prescribing Information – ENDARI (L-glutamine) [cited 2020 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208587s001lbl.pdf.
- Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
- US Food and Drug Administration. Prescribing Information – ADAKVEO® (crizanlizumab-tmca); [cited 2020 Feb 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf.
- Fingar KR, Owens PL, Reid LD, et al. Characteristics of Inpatient Hospital Stays Involving Sickle Cell Disease, 2000–2016: Statistical Brief #251. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD). 2019.
- Shah N, Bhor M, Xie L, et al. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. Health Qual Life Outcomes. 2019;17(1):155.
- Panepinto JA, Brousseau DC, Hillery CA, et al. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005;44(2):182–186.
- Bailey M, Abioye A, Morgan G, et al. Relationship between vaso-occlusive crises and important complications in sickle cell disease patients. Blood. 2019;134(Supplement_1):2167–2167.
- Herquelot E, Morgan G, Lamarsalle L, et al. PSY38 marginal structural model for studying the causal effect between vaso-occlusive crises and occurence of death or complications in the sickle-cell disease patients. Value in Health. 2019;22:S908.
- Shah N, Bhor M, Xie L, et al. Sickle cell disease complications: Prevalence and resource utilization. PLoS One. 2019;14(7):e0214355.
- Rizio AA, Bhor M, Lin X, et al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020;29(6):1533–1547.
- Center for Disease Control and Prevention – National Center on Birth Defects and Developmental Disabilities. Sickle Cell Data Collection Program Report: Data to Action 2018; [cited 2018 Feb 27]. Available from: https://www.cdc.gov/ncbddd/hemoglobinopathies/data-reports/2018-summer/documents/sickle-cell-data-to-action-h.pdf.
- Nietert PJ, Abboud MR, Zoller JS, et al. Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol. 1999;21(5):389–396.
- Woods K, Karrison T, Koshy M, et al. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep. 1997;112(1):44–51.
- Carroll CP, Haywood C, Jr., Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol. 2009;84(10):666–670.
- Epstein K, Yuen E, Riggio JM, et al. Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc. 2006;98(7):1109–1113.
- Benenson I, Jadotte Y, Echevarria M. Factors influencing utilization of hospital services by adult sickle cell disease patients: a systematic review. JBI Database System Rev Implement Rep. 2017;15(3):765–808.
- Hing E, Decker S, Jamoom E. Acceptance of new patients with public and private insurance by office-based physicians: United States, 2013. NCHS Data Brief. 2015;(195):1–8.
- Blinder MA, Vekeman F, Sasane M, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer. 2013; 60(5):828–835.
- The Henry J. Kaiser Family Foundation. Distribution of Medicaid spending by service. 2018 [cited 2020 Mar 27]. Available from: https://www.kff.org/medicaid/state-indicator/distribution-of-medicaid-spending-by-service/view/print/?currentTimeframe=0&print=true&hx0026;sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D.
- Medicare Payment Advisory Commission. Chapter 1: context for Medicare payment policy 2018 [cited 2020 Mar 27]. Available from: http://www.medpac.gov/docs/default-source/reports/mar20_medpac_ch1_sec.pdf?sfvrsn=0